IHN Database

My favourite Supplements

Hormone replacement therapy and risk of surgery

TORONTO, CANADA. Doubts about the benefits of hormone (estrogen) replacement therapy (HRT) continue to surface. Associations between HRT and an increased risk of pancreatitis, systemic lupus erythematosus, asthma, temporomandibular pain, and general abdominal pain have been reported in recent medical literature. Medical researchers have also begun to question the validity of earlier studies "proving" the benefits of HRT; they point out that the women in the HRT groups were generally significantly healthier than the controls.

Researchers at the University of Toronto now report that women who have recently begun estrogen replacement therapy are much more likely to undergo a gallbladder operation (cholecystectomy) or appendectomy (removal of the appendix). Their study involved three groups of women whose medical data was obtained from the Ontario health administrative databases covering 800,000 women over the age of 65 years. One group of women had been prescribed levothyroxine (a thyroid medication), another dihydropyridine calcium-channel antagonists (DCCA) and the third HRT. Estrogen is known to activate inflammation and pain responses while the other two medications have no such effects. After 18 months of follow- up the researchers concluded that women on HRT were twice as likely to end up having surgery to remove their gallbladder or their appendix than were women taking the other medications. They ascribe this increased risk of surgery to the inflammatory effects of estrogen and point out that there is also evidence that new HRT recipients may initially be at an increased risk for cardiovascular disease and osteoarthritis of the hip.
Mamdani, Muhammad M., et al. Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. Canadian Medical Association Journal, Vol. 162, May 16, 2000, pp. 1421-24

category search
Keyword Search

My favourite Supplements

copyright notice